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Population screening for colorectal cancer (CRC) has recently commenced in the United Kingdom supported by the evidence of a
number of randomised trials and pilot studies. Certain factors are known to influence screening cost-effectiveness (e.g. compliance),
but it remains unclear whether an ageing population (i.e. demographic change) might also have an effect. The aim of this study was to
simulate a population-based screening setting using a Markov model and assess the effect of increasing life expectancy on CRC
screening cost-effectiveness. A Markov model was constructed that aimed, using a cohort simulation, to estimate the cost-
effectiveness of CRC screening in an England and Wales population for two timescales: 2003 (early cohort) and 2033 (late cohort).
Four model outcomes were calculated; screened and non-screened cohorts in 2003 and 2033. The screened cohort of men and
women aged 60 years were offered biennial unhydrated faecal occult blood testing until the age of 69 years. Life expectancy was
assumed to increase by 2.5 years per decade. There were 407552 fewer people entering the model in the 2033 model due to a
lower birth cohort, and population screening saw 30345 fewer CRC-related deaths over the 50 years of the model. Screening the
2033 cohort cost d96 million with cost savings of d43 million in terms of detection and treatment and d28 million in palliative care
costs. After 30 years of follow-up, the cost per life year saved was d1544. An identical screening programme in an early cohort (2003)
saw a cost per life year saved of d1651. Population screening for CRC is costly but enables cost savings in certain areas and a
considerable reduction in mortality from CRC. This Markov simulation suggests that the cost-effectiveness of population screening for
CRC in the United Kingdom may actually be improved by rising life expectancies.
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Population screening for colorectal cancer (CRC) has recently
commenced in the United Kingdom supported by the evidence of a
number of randomised trials and pilot studies (Faive et al, 1991;
Mandel et al, 1993; Winawer et al, 1993; Kewenter et al, 1994;
Hardcastle et al, 1996; Kronborg et al, 1996; Towler et al, 1998).
Certain factors are known to influence screening cost-effectiveness
(e.g., compliance and faecal occult blood testing (FOBT) sensitivity),
but it remains unclear whether an ageing population (i.e.
demographic change) might also have an effect.
Colorectal cancer is currently the second commonest cause of
cancer death in western society and its incidence rises steeply from
60 years of age to a peak at 72 years. In the United Kingdom,
average life expectancy is currently estimated to be 75 but is
expected to rise to 82 by 2050. The number of people aged above
60 years is also predicted to rise to 16 million by 2040 (United
Nations, 2000; Office of National Statistics, 2002). There also
remains some debate about the rate of this life expectancy rise.
Oeppen and Vaupel (2002) described life expectancy gains of ‘2.5
years per decade’ although most current government predictions
are closer to 1 year per decade currently.
Mathematical modelling is increasingly used in health-care
programmes to assist in decision making processes, generalise on
trial-based results and extrapolate from intermediate to final end
points (Eddy, 1985; Buxton et al, 1997). The aim of this study was
to simulate a population-based screening setting using a Markov
model and assess the effect of a rising elderly population on CRC
screening cost-effectiveness.
MATERIALS AND METHODS
A Markov model was developed using STATA Version 8.0.
Nineteen Markov disease states were constructed based on the
well-established adenoma-carcinoma sequence (Leslie et al, 2002)
(Figure 1). Dukes A and B cancers were classed as early, Dukes C
cancers as regional and Dukes D cancers as advanced according to
the Turnbull modification of Dukes staging (Dukes, 1932).
Recurrent disease states were absorbed within the ‘detected and
treated’ cancer states.
A Markov model characterises a disease and treatment process
using a finite number of discrete, mutually exclusive health states.
Progression through the model is based on transition matrices,
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swhich determine the probability of moving to a different health
state. The Markov model assumes that the probability of moving to
the next state is determined only by the present state and not by
the path of past states. The model consisted of 19 health states and
each cycle of the model corresponded to 1 additional year of
follow-up. This model assumed that a patient could only move one
state further in the disease progression in a given year (i.e.
undetected low-risk adenoma to undetected high-risk adenoma).
The initial vectors and transition probabilities were established
by a literature search of relevant articles, Pub Med, the Cochrane
database, reference sorting and MESH headings with a search
strategy of studies of CRC, average risk populations, published in
the last decade, peer-reviewed, recognised governmental or
research body websites and modelling studies of CRC (particularly
Markov models).
A longitudinal design of the model was chosen and two cohorts
were considered; an early cohort (commencing in 2003) and a late
cohort (commencing in 2033). The cohorts analysed were assumed
to be subject to age-specific mortality rates (all causes of death) in
England and Wales in 2003, this being calculated using the 2003
Life Tables supplied by the UK Government Actuary Department
(Government Actuary’s Department, 2003). The early cohort, year
2003, consisted of 7053552 people aged 41–50 years. The cohort
aged 11–20 years in 2003 were identified and survival data used to
project the number surviving to 2033 (when they would be 50).
This later cohort, consisting of 6646000 patients, was smaller than
the 2003 cohort due to the lower birth rate in 1970 and 1980
decades. The actuary rates were then manipulated to consider a
rise in life expectancy of both 1 and 2.5 years per decade. The
World Health Organisation CRC mortality rates for the year 2002
were subtracted from the actuary rates to produce the standard all
other cause rates used in the transition matrix (World Health
Organisation, 2002).
The post-operative death rate was set at 3.5% for patients below
80 years, rising to 10% in those above 80 years of age (Smith et al,
2002). It was estimated that 1% of each cohort would be ineligible
for screening at 50 years of age, due to conditions such as
inflammatory bowel disease or CRC diagnosed earlier. Censoring
occurred at the age of 100 years. Initially, the stage-specific annual
death rates used in Frazier’s model were used (0.002 – early cancer,
0.032 – regional cancer, 0.566 – advanced disease). After
verification against the Nottingham screening results, these
probabilities were raised so that the predicted number of deaths
were more in line with those observed in the Nottingham trial.
Frazier’s CRC death probabilities were used in one of the
sensitivity analyses of our model (Frazier et al, 2000b). Appendix
1 lists a number of assumptions underlying the model.
Appendix 2 illustrates the initial vectors, which are the
probabilities of being in each disease state on the patient’s fiftieth
birthday (Hardcastle et al, 1996; Imperiale et al, 2000; Frazier et al,
2000b). The estimates of the prevalence of polyps and the
proportion of polyps that were at high risk at 50 years of age
were taken from Frazier et al (2000a). The proportions of the
population with undiagnosed CRC were chosen to be consistent
with a gradual decline through the states and sensible CRC
incidence rates.
Each patient remained in a disease state for 1 year. The
movement of patients at the end of each year was dependent on the
transition probabilities assigned to that disease state. Although
most transition probabilities remained constant, ‘all other cause
death’, ‘post- and peri-operative death’ and ‘healthy to low-risk
adenoma’ varied by patient age: the latter probabilities being
kindly supplied by Dr Frazier (Frazier, 2002). Appendix 3 lists the
transition probabilities for the main analysis (Frazier et al, 2000a;
Alexander and Weller, 2003). The model considered a steady state
with a cohort of 41- to 50-year-old people entering the model at 50
years of age, running a cohort simulation over a 50-year period.
Appendices 4–6 illustrate the Markov states and the movements
between them (Safi and Beyer, 1993; Winawer et al, 1993;
Hardcastle et al, 1996; Frazier et al, 2000b; Lund et al, 2001;
Frazier, 2002; Nelson et al, 2002; Smith et al, 2002; Government
Actuary’s Department, 2003).
The sensitivity of FOBT for polyps and cancers was taken from
the Cochrane review by Towler et al (2000). Compliance with CRC
screening was altered depending on patient age (Farrands et al,
1984), and the model also considered the feature of screening
detecting cancers that would have become incident in the absence
of screening in a given year. The model also assumed that an
increase in the number of screen-detected cancers and adenomas
would lead to a reduction in the proportion of cancers progressing
to a more advanced stage.
Initially, the sensitivity of FOBT for low- and high-risk
adenomas was taken to be 10% (Frazier et al, 2000a). However,
it became clear that a disproportionate number of low-risk
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Figure 1 The Markov model constructed for colorectal cancer. The Markov model constructed for population screening for colorectal cancer using
FOBT.
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sadenomas were being detected and so the sensitivities were
changed having reviewed data from the Nottingham trial and
Towler Cochrane review of population screening (Hardcastle et al,
1986; Towler et al, 1998).
Population-based screening occurred every 2 years from age 60 to
69 years, which potentially saw five screening rounds and a long
follow-up period (Scholefield et al,2 0 0 2 ) .T h et i m eh o r i z o nf o rt h e
study was 50 years in view of the rising life expectancy. For validation,
the model results were compared with the Nottingham trial by
increasing the number of screening rounds to six and considering the
costs and outcomes up to 8 and 11 years of follow-up (Hardcastle
et al, 1986; Scholefield et al, 2002). A screening period from 50 to 75
years of age was also considered that linked with the original
Nottingham trial, and the results provide a useful picture of the
implications of extending the number of screening rounds.
Resources consumed
It was assumed that a patient with a low-risk adenoma would
undergo one colonoscopy with 98% of patients returning to the
healthy state in the subsequent year. Those with identified high-
risk adenomas were assumed to require three colonoscopies; the
original examination and two surveillance procedures over a
6-year period, before returning to the healthy state.
It was assumed that the primary operative intervention was
similar for all Dukes disease stages. Guidance for post-endoscopic
or -operative follow-up was taken from the British Society of
Gastroenterology 2002 guidelines (British Society of Gastroenter-
ology et al, 2002). Hospital-based surgical follow-up occurred for
Dukes A to C cancers (over a 10-year period) and was modelled to
involve four colonoscopies, eight clinic appointments, one CT and
two ultrasound scans. Dukes D cancer patients either died in the
year of diagnosis or were moved into the palliative care state the
following year. The resources consumed by the detection and
further treatment of recurrent disease were absorbed into the
respective disease (detected and treated early or regional/palliative
care) cancer disease states.
Costs
Evidence for the costing of the model came almost exclusively
from NHS reference costs (British Society of Gastroenterology
et al, 2002; Department of Health, 2005). The individual costs of
interventions are listed in Appendix 7. A treatment-level
perspective of costs was taken for the analysis. The cost for
hospital-based follow-up procedures was spread evenly over the
period of surveillance.
Each year was considered separately with the number of persons
in each disease state being multiplied by the cost of that state; the
total cost of each cohort being derived from the sum of these yearly
costs. Costs and outcomes were discounted at a 3.5% rate for the first
30 years of follow-up and 3% thereafter, with sensitivity analyses
varying the rate to 0 and 10%. All costs were considered in sterling
and updated to 2005 prices using the GDP deflator (HM Treasury,
2002). The costs of the test, postage, processing and subsequent
investigation of positive tests were distributed across the disease
states. The initial screening round occurred in the base year (year 0).
The number of detected pathologies, the number of CRC deaths,
the cost of care and the effect of screening on CRC incidence and
mortality were investigated and the cost of management examined.
The four model outcomes, namely early and late-screened and
non-screened cohorts, were then compared.
RESULTS
Owing to the lower birth rate in the later cohort (2033), there were
407552 fewer people entering the model. As the adenoma-
carcinoma sequence was the key process in the model, the sojourn
time was examined and found to be clinically plausible (Figure 2).
The reduction in the incidence rate of CRC was found in the
screened cohort for both early and late cohorts; this fall first
becoming apparent in the nineteenth year (cohort age 60–69
years), with clear divergence of the lines by 22 years (Figure 3). The
distributions of all cancers detected in the screened group, by
stage, were 43% (211041) Dukes A and B, 33% (162831) Dukes C
and 24% (117269) Dukes D in the early cohort.
Deaths from CRC reached 194607 (65983 discounted) at model
cessation in the screened group of the later cohort. There were
30345 fewer CRC deaths than the non-screened cohort. Overall,
the relative rate of CRC mortality in the screened cohort at 30 years
was 0.86 (Table 1).
Considering the screened late cohort, the trend of costs followed
the marked rise in the number of low-risk adenomas detected by
screening, with d5.8 million more spent on managing low-risk
adenomas. High-risk adenoma management (detection, treatment
and subsequent surveillance) cost d6.2 million more (Table 2).
Early cancers proved to be the most costly stage to treat and
survey, with the total costs reaching d556.3 million and d53.9
million, respectively. Overall, the cost of the screening programme
was considerable, amounting to d96.2 million (Table 3). This
represented 7% of the total cost of managing CRC in this 10-year
cohort, the other major cost being primary treatment and
detection, which cost d1204 million (83%).
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Figure 2 Mean sojourn time of the Markov model for progression
through the adenoma-carcinoma sequence.
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Figure 3 Colorectal cancer incidence rate in the late cohort with or
without screening (60–69).
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sAlthough screening led to a marked increase in high-risk
adenoma detection (31480 additional detected), there were 6495
fewer early stage cancers, 19209 fewer regional cancers and 19046
fewer advanced cancers. Owing to the reduced number of cancers
treated, the cost of detecting, treating and caring for regional and
advanced cancers reduced by d43 million and d30 million,
respectively. Overall, screening the late cohort for CRC saw a cost
rise by d26 million (Table 3).
The cost-effectiveness of biennial FOBT screening of the late
cohort was found to be d1544 per life year saved after 30 years of
follow-up. Considering an identical screening programme under-
taken on the early cohort (2003), the cost per life year saved was
d1651 (Table 4).
The cost per life year saved is initially very expensive due to the
in-built costs of running a national screening programme. The
overall cost of the programme would be expected to fall
Table 1 Number of subjects requiring care due to colorectal pathology in the late (2033) cohort in a screened population from 60 to 69 years of age
Detected and treated primary disease
Years of
follow-up
Discounted cumulative
deaths from CRC n
(undiscounted)
Low–risk
adenoma n
(undiscounted)
High-risk
adenoma n
(undiscounted)
Early cancer
n (undiscounted)
Regional cancer
n (undiscounted)
Advanced cancer
n (undiscounted)
Late cohort – screened
1–20 16901 (28262) 35625 (60860) 44643 (74053) 30814 (50592) 21074 (34194) 13835 (22397)
21–40 52869 (132356) 28265 (68375) 51490 (138967) 41853 (116417) 32224 (91394) 23239 (66592)
41–50 65983 (194607) 2501 (10995) 13366 (58848) 13142 (57881) 11321 (49869) 8686 (38270)
Total 65983 (194607) 66392 (140230) 109499 (271868) 85810 (224891) 64619 (175458) 45761 (127260)
Late cohort – not screened
Total 77573 (224952) 24557 (56427) 91909 (240388) 86107 (231386) 71440 (194667) 52990 (146306)
England and Wales population. Life expectancy increasing at 2.5 years per decade. 2033 population of 6646000. Screening with biennial unhydrated haemoccult faecal occult
blood testing (FOBT).
Table 2 Costs of treating subjects with colorectal pathology in the late (2033) cohort in a screened population from 60 to 69 years of age
Detecting and treating primary disease Cost of surveillance
Palliative
care
Low-risk
adenoma
High-risk
adenoma
Early
cancer
Regional
cancer
Advanced
cancer
False
positives
High-risk
adenoma
Early
cancer
Regional
cancer
Years of
follow-up d million d million d million d million d million d million d million d million d million d million
Late cohort – screened
1–20 5.0 5.8 192.7 127.5 54.2 12.8 4.8 11.9 6.3 13.9
21–40 4.3 7.6 274.4 207.7 97.1 10.4 11.8 31.3 15.9 26.8
41–50 0.5 2.0 89.2 75.9 37.8 0.0 3.0 10.6 6.2 9.8
Total 9.8 15.4 556.3 411.2 189.1 23.2 19.7 53.9 28.3 50.4
Late cohort – not screened
Total 4.0 12.8 557.1 454.2 219.1 0 16.1 53.4 31.3 78.4
England and Wales population, 2005 costs in pounds sterling discounted at 3.5% rate for the first 30 years of follow-up and 3% thereafter. Life expectancy increasing at 2.5 years
per decade. 2033 population of 6646000. Screening with biennial unhydrated haemoccult faecal occult blood testing (FOBT).
Table 3 Comparing the costs of treating subjects with colorectal pathology with or without screening from 60 to 69 years of age: considering a 2003
(early) and 2033 (late) cohort
2003 (early cohort) 2033 (late cohort)
Non-screened Screened Non-screened Screened
Early cohort Early cohort Late cohort Late cohort
d million (%) d million (%) d million (%) d million (%)
Screening — 100 (7) — 96.2 (7)
Primary detection and treatment 1208.2 (88) 1174.0 (83) 1247.2 (87) 1203.8 (83)
Surveillance 95.2 (7) 96.8 (7) 100.9 (7) 101.9 (7)
Palliative care 72.4 (5) 46.4 (3) 78.4 (5) 50.4 (4)
Total cost of colorectal cancer care 1376 1417 1426 1452
2003 population of 7053552; 2033 population of 6646000. England and Wales population, 2005 costs in pounds sterling discounted at 3.5% rate for the first 30 years of follow-
up and 3% thereafter. Life expectancy increasing at 2.5 years per decade.
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sdramatically at the cessation of screening (at 69 years), whereas the
benefits of the screening programme in terms of effect would
continue. Overall, screening reduced the lifetime risk of CRC from
8.6 to 7.9%, with a relative rate reduction of 6% at 30 years. The
relative rate reduction in CRC mortality was 14% over the same
time period.
Extending the number of screening rounds
The extended screening period (50–75) saw 169246 CRC deaths,
25361 fewer cancer deaths than the baseline model with fewer
screening rounds. The relative rate of CRC mortality in the
screened cohort at 30 years was 0.73. This improved detection rate
and mortality reduction came at a cost of d141 million for
screening, with an additional d99 million overall. The cost-
effectiveness of screening from 50 to 75 was d1501 per life year
saved, so proved to be similar in cost effectiveness to the 60–69
screening regiment. The lifetime risk of CRC was reduced from 8.6
to 6.3%, with a relative rate reduction of 27% at 30 years.
Comparing life expectancy increases of 2.5 years vs 1 year
per decade (screening from 50 to 75)
Compared with a 2.5-year per decade life expectancy rise, the
1-year rise saw fewer adenomas and cancers detected across the
board. In the non-screening model in the late cohorts, the longer
life expectancy saw an additional 51631 early cancers, 44377
regional cancers and 52029 additional CRC deaths over the 50-year
period. The average life expectancy dropped from 90 to 84 years.
The cost of CRC care in all areas was less and, although totalling
d1191.6 million, was d234.9 million less than for those with a
higher life expectancy.
DISCUSSION
The cost per life year saved by screening was d1651 for the 2003
cohort and d1544 for the 2033 cohort at 30 years follow-up.
Although screening of the cohort caused a relative cost increase in
CRC care overall, it appears that the cost-effectiveness of FOBT
screening does not deteriorate and may actually improve in a
population with rising life expectancy.
A smaller increase in life expectancy of 1 year per decade saw an
earlier age of death, fewer pathologies detected, less costs and a
more favourable cost-effectiveness ratio. There was no difference
in the relative risk reduction of CRC mortality.
Despite the lower birth rate in the later cohort and identical CRC
incidence rates, it appears that the cost of CRC care without
population screening would be increased compared with 30 years
previously, which has resource implications for the UK health
service (Table 3). The cost implications of such a trend included an
additional d39 million for primary detection and treatment, d5.7
million for surveillance and d6 million for palliative care services.
The overall cost of CRC care rose by 3.7% to d1426 million.
Strengths and limitations
Although the sojourn time from high-risk adenoma to early cancer
appeared to fit with current thinking (Figure 2), and model
checking had corrected many small changes, it was clear that the
mortality data (both for CRC and all cause) was deficient. Despite
the changes made using the CRC rates from the Nottingham trial
data, at 20 years follow-up, the number of CRC deaths was 2%
above that of the trial with a CRC incidence 13% higher than the
Nottingham screening population. These serve as a reminder that
the results should be considered as projections of a situation up to
the year 2083, with many potential factors affecting it.
This research commenced in 2002 at which time a UK-based
national screening programme was still in the pilot stage with no
government commitment for rolling it out. When the roll out was
announced, Scotland elected to screen from 50 to 69 whereas
England was initially restricted to 60–69. Reducing the number of
screening rounds seems to slightly reduce the cost-effectiveness of
screening.
Certain areas of Markov models remain unsatisfactory, one of
which is the Markovian assumption. This states that the
probability of leaving any particular state in the model is
independent of the time spent in that state or the pathway
followed to end up in that state. This means that the model has no
memory, which is not an ideal situation when considered from a
medical perspective (Drummond et al, 1997). Despite the
weaknesses of Markov models, gaining an insight into this
research question without such a mathematical model would be
difficult. As only a 10-year cohort in England and Wales has been
considered, it does not fully reflect all age groups in the United
Kingdom, and rates would fluctuate further depending on the
country in question. In a critical review of modelling systems for
screening, Karnon et al (2007) highlighted the lack of methodo-
logical studies in this area and that there were no studies reporting
direct empirical comparisons of alternative methodologies. As
recommended in their review, we took separate disease stages
(early, regional and advanced) and considered their post-diagnosis
disease progression separately (Karnon et al, 2007).
As with any model, there could be improvements and refinements.
Future models could use gender-specific and more refined age-
specific compliance rates for the uptake of screening. The most
reliable source for this would probably be the national roll out
study published by Alexander and Weller (2003). In terms of costs,
the study by Trueman et al (2007) is probably the most
comprehensive costing review of bowel cancer services in the
literature to date.
This model is dependent on the reliability of three key papers;
Frazier’s model, the Nottingham FOBT trial (Hardcastle et al,
1996) and the UK pilot of population CRC screening (Alexander
and Weller, 2003), but each of these has been recognised as reliable
data at the time of publication. Frazier’s study appears to be
trusted and respected, being one of the more robust studies of its
kind (Alexander and Weller, 2003). In an ageing population, the
proportion of women will increase and the ethnic distribution may
well change – neither of these areas were focussed on specifically in
the paper and would be areas for future study.
Only direct hospital costs were considered here and the
top-down approach taken for the NHS reference costs may
underestimate the cost of treatment. Increasing use of adjuvant
and palliative chemotherapy, intensive follow-up, metastatic cancer
resections and increased resources for palliative care services will
only raise the CRC costs further. Also, the initial costs of setting up a
screening programme were not considered but are well recognised to
Table 4 Comparing the cost per life year saved by screening a
population from 60 to 69 years of age: 2003 and 2033 cohorts
Screening
group
Person
years
Cost of
care d million
Cost per life
year saved
at 30 years d
Early cohort (2003)
Not screened 167361488 793.0
1650.8
Screened 167424446 896.9
Late cohort (2033)
Not screened 159711908 772.7
1544.2
Screened 159775486 888.0
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sbe considerable (Garvican, 1998). These cost results could therefore
be considered the minimum funds required (Dube et al,1 9 9 7 ;
Memon and Beckingham, 2001; Ward et al, 2004).
Discounted costs and benefits were presented and the rates for
costs were reduced from 3.5 to 3% after 30 years of follow-up as per
standard economic evaluations (Drummond et al, 1997). Discount-
ing benefits has a considerable effect on the number of CRCs
detected and the overall mortality rate, and the whole process of
discounting deaths and other outcomes remains debatable.
Using a cost per QALY measure as the cost-effectiveness
outcome, rather than cost per life year gained, might make the
results relevant to a wider audience and more easily comparable
with non-cancer treatments. However, as the QALY coefficient in
CRC screening is still considered to equal approximately one, it is
likely that one life year gained continues to be comparable with
one QALY in CRC screening (Whynes et al, 1994).
An alternative approach to sensitivity analysis could have been
used, altering the chosen transition probabilities until a 10%
change in the outcome measure was detected. Considering the
transition probabilities for the movement through the adenoma-
carcinoma sequence, the effect of a changing rate of transition has
a considerable effect on the number of high-risk adenomas and
cancers. Reducing the rate of low-risk to high-risk adenoma
progression saw a 41–42% reduction in high-risk adenomas, early
cancers and cumulative CRC deaths while also reducing total costs
by 41% (d581.2 million less). Surprisingly, equally sized cohorts
made little difference to costs (5% increase), whereas using the
Frazier’s cancer mortality rates increased costs by only 10%. Of all
the cost changes to affect the results, altering the discount rate
between 0 and 10% caused a huge change in results, with
undiscounted costs (over the 50-year time horizon) being 177%
higher. However, the costs are routinely discounted and so this
figure is unrealistic in health economic terms.
Only the Minnesota randomised trials of FOBT screening have
found a fall in CRC incidence, felt to be due to the high rate of
colonoscopy with its annual screening programme. In this model,
it took 10 years after screening started for any change in incidence
to become evident but included a larger cohort. An overall gain in
life expectancy of 2.4 months (screening from 50 to 75, 2.5 years
per decade life expectancy gains) is higher than the National pilot
figure of 14–16 days, with gains reducing to 1 month if lower life
expectancy gains are used. Overall, the gains are not great and the
World Cancer Report summarises the situation well: the screening
benefit per person is small in terms of overall life expectancy (1–4
weeks), but the benefit is great for the 5% destined to have cancer
(World Health Organisation, 2003).
CONCLUSION
Population screening for CRC is costly but enables cost savings in
certain areas and a considerable reduction in mortality from CRC.
This Markov simulation suggests that the cost-effectiveness of
population screening for CRC in the United Kingdom may actually
be improved by rising life expectancies.
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Appendix 1
Markov model: assumptions and screening model variables
Appendix 2
Initial vectors for the Markov model
Assumptions
Dealing with an England and Wales population
Life expectancy continues to improve at the present rate
All subjects entering the model were assumed to be healthy or with undiagnosed adenoma or CRC
Stage-specific survival remains the same
Colorectal cancer remains an age-related disease
Each subject remains in the Markov state for a full year
The sojourn time from adenomatous polyp to cancer does not alter
Model variables
Sensitivity of unhydrated faecal occult blood test for colorectal cancer
Colorectal cancer 33% Towler et al (2000)
High-risk adenoma 7.5% Towler et al (2000
a
Low-risk adenoma 2.5% Towler et al (2000
a
Age-specific compliance with screening 55% 50–64 Farrands et al (1984)
48% 65–69 Farrands et al (1984)
43% 70–74 Farrands et al (1984)
Screening unit costs FOBT d5.53 Processing of test d0.21
Screening with biennial unhydrated haemoccult faecal occult blood testing (FOBT). Sensitivity reduced, recognising that a higher proportion of high-risk to low-risk adenomas
would be detected.
aInitially, 10% sensitivity for both low- and high-risk adenomas used, but unrealistic detection rate for FOBT.
Disease states Initial vector References (date)
Healthy 0.78875 One minus all other states
Low-risk adenoma 0.206 Frazier et al (2000a,b)
High-risk adenoma 0.004 Frazier et al (2000a,b)
Early cancer 0.001 Hardcastle et al (1996); Imperiale et al (2000)
Regional cancer 0.0002 Hardcastle et al (1996); Imperiale et al (2000)
Advanced cancer 0.00005 Hardcastle et al (1996); Imperiale et al (2000)
All other states 0
A cohort of 50-year olds (population of England and Wales).
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Transition probabilities for the Markov model
Appendix 4
Markov states 1–6 and the links to other Markov states in the screening age range
Variable Value References (date)
Prevalence of polyps at age 50 years % 21 Frazier et al (2000a,b)
Proportion of all polyps at age 50 years that are of high risk % 2 Frazier et al (2000a,b)
Annual transition probabilities
Normal epithelium to low-risk adenoma (age specific)
50–54 years 0.005 Frazier (2002)
55–59 years 0.0065 Frazier (2002)
60–64 years 0.008 Frazier (2002)
Over 65 years 0.0095 Frazier (2002)
Low-risk to high-risk adenoma 0.02 Frazier et al (2000a,b)
High-risk adenoma to early cancer 0.05 Frazier et al (2000a,b)
Early to regional cancer 0.28 Frazier et al (2000a,b)
Regional to advanced cancer 0.35 Alexander and Weller (2003) Estimate
Probability of symptomatic presentation of colorectal cancer
Early cancer 0.25 Frazier et al (2000a,b)
Regional cancer 0.45 Alexander and Weller (2003) Estimate
Advanced cancer 1 Frazier et al (2000a,b)
Annual colorectal cancer-specific mortality rates
Early cancer 0.0542 Hardcastle et al (1996); ACPGBI (2002)
Regional cancer 0.1677 Hardcastle et al (1996); ACPGBI (2002)
Advanced cancer 0.6469 Hardcastle et al (1996); ACPGBI (2002)
Post/peri-operative death rates
Early cancer 0.057 ACPGBI (2002)
Regional cancer 0.069 ACPGBI (2002)
Advanced cancer 0.119 ACPGBI (2002)
State number Initial Markov state Next Markov state (no.) Transition probability Reference (date)
1 Healthy Low-risk adenoma (2) Age specific Frazier (2002)
Death from all other causes (16) Age specific Government Actuary’s
Department (2003)
Remain (1) *
False positive (19) (0.03/2)*compliance
2 Low-risk adenoma High-risk adenoma (3) 0.02*(1 ‘compliance’*sensitivity/2) Frazier et al (2000a,b)
Detected and treated low-risk
adenoma and discharged (7)
‘comp’*0.025/2+
(1 ‘sens0*’comp’/2)*0.0009
Hardcastle et al (1996)
Death from all other causes (16) Age specific Government Actuary’s
Department (2003)
Remain (2) *
3 High-risk adenoma Early cancer (4) 0.05*(1 ‘sens’*sens/2) Frazier et al (2000a,b)
Detected and treated high-risk
adenoma (8)
‘comp’*0.075/2+
(1 ‘comp’*sens/2)*0.019
Hardcastle et al (1996)
Death from all other causes (16) Age specific Government Actuary’s
Department (2003)
Remain (3) *
4 Early cancer Regional cancer (5) 0.28*(1 ‘comp’*sens/2) Frazier et al (2000a,b)
Detected and treated early cancer (9) ‘comp’*0.33/2+
(1 ‘comp’*sens/2)*0.18
Frazier et al (2000a,b)
Death from all other causes (16) Age specific Government Actuary’s
Department (2003)
Remain (4) *
5 Regional cancer Advanced cancer (6) 0.35*(1 ‘comp’*’sens’/2) Alexander and Weller (2003 )Estimated
Detected and treated regional
cancer (10)
‘comp’*0.33/2+
(1 ‘comp’*’sens’/2)*0.45
Alexander and Weller (2003) Estimated
Death from all other causes (16) Age specific Government Actuary’s
Department (2003)
Remain (5) *
6 Advanced cancer Detected and treated advanced
cancer (11)
*
Death from all other causes (16) Age specific Government Actuary’s
Department (2003)
Death from all other causes is an age-specific probability and so varies within the model. *For each state, the transition probabilities for each state must add up to one. 2005 costs
in pounds sterling discounted at 3.5% rate for the first 30 years of follow-up and 3% thereafter.
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Markov states 9–12 and the links to other Markov states in the screening age range
Appendix 6
Markov states 13–19 and the links to other Markov states in the screening age range
State number Initial Markov state Next Markov state (no.) Transition probability Reference (date)
7 D/T low-risk adenoma Death from all other causes (16) Age specific Government Actuary’s Department (2003)
Healthy (1) *
Peri/post-operative death (18) 0.0001 Nelson et al (2002)
Remain (7) 0.019 Lund et al (2001)
8 D/T high-risk adenoma Peri/post-operative death (18) 0.001 Nelson et al (2002
Surveillance high-risk adenoma (13) *
Death from all other causes (16) Age specific Government Actuary’s Department (2003)
9 D/T early cancer Peri/post-operative death (18) 0.057 ACPGBI (2002)
Surveillance early cancer (14) *
Death from all other causes (16) Age specific Government Actuary’s Department (2003)
Death from colorectal cancer (17) 0.0542 Hardcastle et al (1996); ACPGBI (2002)
10 D/T regional cancer Peri/post-operative death (18) 0.069 ACPGBI (2002)
Surveillance regional cancer (15) *
Death from all other causes (16) Age specific Government Actuary’s Department (2003)
Death from colorectal cancer (17) 0.1677 Hardcastle et al (1996); ACPGBI (2002)
Remain (10) 0.025
11 D/T advanced cancer Peri/post-operative death (18) 0.119 ACPGBI (2002)
Palliative care (12) *
Death from all other causes (16) Age specific Government Actuary’s Department (2003)
Death from colorectal cancer (17) 0.6469 Hardcastle et al (1996); ACPGBI (2002)
12 Palliative care Death from all other causes (16) Age specific Government Actuary’s Department (2003)
Death from colorectal cancer (17) 0.6469 Hardcastle et al (1996); ACPGBI (2002)
Remain (12) *
Death from all other causes is an age-specific probability and so varies within the model.
[2]/T, detected and treated. *For each state, the transition probabilities for each state must
add up to one. 2005 costs in pounds sterling discounted at 3.5% rate for the first 30 years of follow-up and 3% thereafter.
State number Initial Markov state Next Markov state (no.) Transition probability Reference (date)
13 Surveillance Healthy (1) 0.1667
High-risk adenoma Detected and treated low-risk adenoma (7) 0.014 Winawer et al (1993); Lund (2002)
Detected and treated high-risk adenoma (8) 0.023 Winawer et al (1993)
Death from all other causes (16) Age specific Government Actuary’s Department (2003)
Remain (13) *
14 Surveillance Healthy (1) 0.125
Early cancer Death from all other causes (16) Age specific Government Actuary’s Department (2003)
Death from colorectal cancer (17) 0.0239 Hardcastle (2000)
Remain (14) *
15 Surveillance Healthy (1) 0.125
Regional cancer Death from all other causes (16) Age specific Government Actuary’s Department (2003)
Death from colorectal cancer (17) 0.0649 Hardcastle (2000)
Remain (15) *
16 Death from other cause Permanent state — —
17 Death from colorectal cancer Permanent state — —
18 Peri/post-operative death Permanent state — —
19 False-positive tests Healthy (1) *
Death from all other causes (16) Age specific Government Actuary’s Department (2003)
Peri/post-operative death (18) 0.0001
Death from all other causes is an age-specific probability and so varies within the model. *For each state, the transition probabilities for each state must add up to one. 2005 costs
in pounds sterling discounted at 3.5% rate for the first 30 years of follow-up and 3% thereafter.
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Cost of interventions in colorectal cancer care
Unit cost (d)
Sensitivity analysis
Procedure Base Lowest Highest References (date)
Screening
Faecal occult blood test 5.53 4.43 6.64 Department of Health (2005)*
,+
Processing of test 0.21 0.17 0.25 Whynes (2002)*
Investigation and intervention
Clinic appointment 97 85 113 Department of Health (2005) FUA 114
Computed tomography (CT) scan 86 63 101 Department of Health (2005) RBC6
Ultrasound of liver 67 51 89 Department of Health (2005) RBC2
Colonoscopy 133 122 223 Department of Health (2005) F35
Surgical resection and follow-up
Early 4756.09 3804.87 5707.31 Alexander and Weller (2003)*
,+
Regional 4518.18 3614.54 5421.81 Alexander and Weller (2003)*
,+
Advanced 2378.05 1902.44 2853.66 Alexander and Weller (2003)*
,+
Post-operative chemotherapy 276 147 463 Department of Health (2005) X99COC
Palliative care 2909.21 2327.36 3491.05 Alexander and Weller (2003)*
,+
d pounds sterling at 2005 costs. *Updated to 2005 costs. +Ranges of costs calculated as 20% above and below base rate. Department of Health: NHS reference costs. BSG:
British Society of Gastroenterology Guidelines.
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